Difference between revisions of "Interferon alfa-2a (Roferon-A)"
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
Warner-admin (talk | contribs) m |
||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | |||
*[[Chronic myelogenous leukemia]] | *[[Chronic myelogenous leukemia]] | ||
*[[Follicular lymphoma]] | *[[Follicular lymphoma]] | ||
| Line 13: | Line 12: | ||
*[[Neuroendocrine tumors]] | *[[Neuroendocrine tumors]] | ||
*[[Renal cancer]] | *[[Renal cancer]] | ||
| − | *[[ | + | *[[Squamous cell carcinoma (SCC)]] |
==Patient drug information== | ==Patient drug information== | ||
| Line 28: | Line 27: | ||
[[Category:Cytokines]] | [[Category:Cytokines]] | ||
| − | |||
[[Category:Chronic myelogenous leukemia medications]] | [[Category:Chronic myelogenous leukemia medications]] | ||
[[Category:Follicular lymphoma medications]] | [[Category:Follicular lymphoma medications]] | ||
| Line 34: | Line 32: | ||
[[Category:Neuroendocrine tumor medications]] | [[Category:Neuroendocrine tumor medications]] | ||
[[Category:Renal cancer medications]] | [[Category:Renal cancer medications]] | ||
| − | [[Category: | + | [[Category:Squamous cell carcinoma (SCC) medications]] |
[[Category:Drugs FDA approved in 1986]] | [[Category:Drugs FDA approved in 1986]] | ||
Revision as of 21:53, 2 February 2018
General information
Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood.[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Chronic myelogenous leukemia
- Follicular lymphoma
- Melanoma
- Neuroendocrine tumors
- Renal cancer
- Squamous cell carcinoma (SCC)
Patient drug information
History of changes in FDA indication
- 6/4/1986: Initial FDA approval